BUS6900 IP Strategy and ManagementNOVARTIS GROUP JianGu SedemYener Elias Jaime Porras
Context • About Novartis Company • IP Portfolio • IP strategy and management • Future plan for Novartis Company
About Novartis Company • multinational pharmaceutical company • offers a wide range of healthcare products through our Pharmaceuticals, Vaccines and Diagnostics, Sandoz and Consumer Health Divisions. • a full member of the European Federation of Pharmaceutical Industries and Associations. • was created in 1996 from the merger of Ciba-Geigy and Sandoz Laboratories. • Main local is Switzerland. • In 1998 the company made headlines with its biotechnology licensing agreement with the UC Berkeley Department of Plant and Microbial Biology.
Details • CEO :Dr. Daniel Vasella, M.D. • Employees : 98200 • Market Cap : 107,150,055,000 • Auditor : PriceWaterHouse Cooperation A.G. • Gross Margin : 71.3 • Profit Margin : 20.3 • EBIT Margin : 20.9 • Return on Equity : 23.9 • Return on Capital: 22.9 • Return on Assets : 14.8
Pharmaceuticals Products of Novartis Company • Diovan- $5.0 B sales(2007)- Hypertension • Gleevec - $3.1 B- for Chronic myeloid leukemia • Zometa- $1.3 B (2007)- Cancer complications • Sandostatin - $1.0 B (2007) - Acromegaly • SandimmunNeoral- $944 M (2007)- Transplantation • Femara- $937 M (2007)- Breast cancer • Lotrel- $748 M (2007)- Hypertension • Voltaren- $747 M (2007)- Inflammation • Trileptal- $692 M (2007)- Epilepsy • Lescol- $665 M (2007)- cholestrol • Exelon- $632 M (2007)- Alzheimer's disease • Comtan- $420 M (2007)- Parkinson's disease • Tegretol- $413 M (2007)- Epilepsy • Lucentis- $393 M (2007)- Age-related macular degeneration • Ritalin- $375 M (2007) - ADD • Exjade- $357 M (2007) – Iron chelator • Tobramycin- $273 M (2007)- Cystic fibrosis • Termalgin - (Paracetamol and compounds.) - Treatment of fever and light pain.
Major therapeutic areas: • autoimmunity/transplantation/ inflammatory disease • cardiovascular disease • diabetes • gastrointestinal disease • infectious diseases • musculoskeletal disease • neuroscience • oncology • ophthalmology • respiratory disease
Novartis IP portfolio!!! • involves coordination and quality control of biologics patenting and freedom-to-operate analysis across all disease areas, platforms, and functions within NIBR. • is Director of Intellectual Property • John T. LiPatents, Head, Biology & Biologics, Novartis Institutes forBiomedical ResearchNovartis
Novartis IP portfolio and It’s Process!!! • operates in 140 countries and currently has 75 new treatments in the pipeline • More than 12,000 US Granted Patents • Patent Mapping Reports provide specific and detailed insights into patenting activities of specific Fortune 500, NASDAQ and S&P 500 organisations • Is gearing up to break new CSR ground, with a funding proposal for neglected disease research that advantages IP rights to strike a balance between corporate return on investment and the provision of vital treatments to penniless developing countries.
Novartis IP portfolio and It’s Process!!! • The International Patent Classification (IPC) is a hierarchical system in which the whole area of technology is divided into a range of sections, classes, subclasses and groups. • have undertaken a concordance (matching) of IPC (International Patent Classification ) and (US Patent Classification) UPC to NAICS (North American Industrial Classification System -this new, uniform, industry-wide classification system has been designed as the index for statistical reporting of all economic activities of the U.S., Canada, and Mexico).
Future Planning • Novartis Buys Additional 51.7% Stake in Speedel company. • Make e-business partnership: World Online and Novartis plan together to build initially a pan-European portal and an e-commerce platform that will become the first of its kind within the healthcare and wellness arena. • 30% Increase In US Supplies Of Fluvirin Influenza Vaccines And Delivery Of 40 Million Doses. • will be replaced by two Novartis execs who will oversee development in newly created roles
Thank you!!! Any Question?